Suppression of CD56 bright NK cells in breast cancer patients is associated with the PD-1 and TGF-βRII expression.
Elaheh ArianfarSeyed Reza KhandooziSaeed MohammadiAli MemarianPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
subset of BC patients. It specifies their potential incompetence and outlines decrement of their anti-tumor activity, which could be interrelated with the tumor pathogenesis, TME immunosuppression, and so disease progression. The induction of compensatory mechanisms revives NK cells function and could be used in combination with the conventional treatments as a putative therapeutic approach for targeted immunotherapy.